The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
about
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisEpigenetic modulators as therapeutic targets in prostate cancerEpigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancerStrategies to Inhibit Myc and Their Clinical ApplicabilityThe Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood SarcomaCombined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaBET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.Targeting BET bromodomain proteins in solid tumorsBET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine effortsTargeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Bromodomain inhibitors and cancer therapy: From structures to applications.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.BET inhibitors as novel therapeutic agents in breast cancer.BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways.BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis.JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells
P2860
Q27728041-DEFDD57A-5682-4A2C-A5F6-4BA13989D0A0Q28071912-FF21E624-C5B7-4CAB-8B48-E89A6636460BQ28076548-A69601C8-574B-44CB-9774-6F6C99D8FCB2Q33591618-92BBAC55-4A91-4F33-A55B-0F4C741D238CQ33798766-7922497D-0BA0-4283-95EA-249B4C64C997Q36303678-5AAEF4D9-8514-4BA4-8D77-484118850FE9Q36918007-A39F5E37-2985-4A07-B1B9-DFFBF683616DQ37123636-AB1DBC5A-5FE3-4821-A9D6-83993B937AC5Q37536618-95DFB886-1504-4345-B936-037A75A6AE82Q37619860-D89FFC00-920B-4A3B-84A7-63C5381F48D8Q37624355-539C12B1-49BE-4D79-B02E-7CA00F7418A8Q37718370-0263D46D-A198-4805-88FF-FCFC29F62137Q37733990-8DDD4E93-F43C-48BE-B6EE-97A177369CFDQ38708376-29079773-E33C-48E2-A24E-A50C0545ED00Q38712272-3B560EA5-68D1-46D9-96E7-3069484615B6Q39027056-8AC921F2-844C-43E5-8F35-30FF6A382AEEQ39204274-DEB3E952-408A-4282-B549-314EEA0D476AQ40951274-DA9DEDB7-BB43-4315-9719-FE48F98DF543Q41098457-D6464AF2-0B16-422E-853D-D14A05B081CBQ41637362-398C7487-C01F-4FA7-A560-C0598D4C6B6EQ41738818-4CEA6EC0-A605-4894-9CB2-74BB001D7BC7Q42321605-DE5BFAE3-05FB-485E-9683-5266AE5A74B9Q42378528-BBD4B2E8-4B2E-4A1E-B82C-4F466D15BE44Q42540751-66C7BEBD-6683-49D8-9BDB-AB99B28D00A9Q42778048-AF3D74DD-0789-473D-83CD-17F728A9BC0CQ43238483-DE7B2899-B5FD-4F6F-9E15-B8F579AA453FQ47350877-70CA682E-1DC0-4FFE-BDA9-EEB574D7B5AEQ47398665-03832A6F-90B0-4832-8AB3-F7AC581DCCD9Q50304177-D002B74E-9C7F-4BF8-92AC-B3024CA86F1EQ52719995-9D34D129-9805-4045-897F-0F35CF3AAC5CQ58553987-DA81CDF5-E7FA-40A2-A702-5293768CE262
P2860
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@en
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@nl
type
label
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@en
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@nl
prefLabel
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@en
The BET bromodomain inhibitor ...... ient-derived xenograft models.
@nl
P2093
P2860
P921
P356
P1433
P1476
The BET bromodomain inhibitor ...... tient-derived xenograft models
@en
P2093
A L Miller
J D Christein
J E Bradner
J H Richardson
J P Arnoletti
P2860
P2888
P304
P356
10.1038/ONC.2015.126
P407
P577
2015-05-11T00:00:00Z
P6179
1026941261